Core Insights - The article discusses the recent developments in the pharmaceutical industry, particularly focusing on the approval of innovative drugs and their market implications [12][15]. Market Performance - The pharmaceutical and biotechnology indices experienced a slight decline, with the medical biotechnology index down by 0.29%, outperforming the Shanghai Composite Index by 0.05 percentage points [5]. - The Hang Seng Healthcare Index fell by 2.26%, while the Hong Kong innovative drug ETF decreased by 2.18% [5]. Innovative Drug Approvals - Eight innovative drugs received approval last week, including: - **Fitusiran** for hemophilia A or B [11]. - **库莫西利** (Kumosili), a CDK2/4/6 inhibitor for HR+/HER2- breast cancer, which is expected to address resistance issues seen with existing treatments [12][14]. - **玛帕西沙韦** (Marpasiwe), an antiviral for influenza, showing significant efficacy in clinical trials [15]. Clinical Trials and Research - The article highlights ongoing clinical trials, including a significant Phase III trial for **库莫西利**, which demonstrated a median progression-free survival (PFS) of 16.62 months, extending PFS by 9.16 months compared to the control group [14]. - A total of 96 new clinical trial registrations were disclosed, with 30 trials in Phase II or higher [7]. Industry Trends - The innovative drug sector remains a key investment focus, with ongoing business development activities and cross-border transactions indicating strong confidence in domestic innovation capabilities [6]. - The global market for CDK4/6 inhibitors is projected to reach approximately $24 billion, driven by increasing indications for early-stage breast cancer [12]. Challenges - The article notes that resistance to CDK4/6 inhibitors remains a significant challenge, with about 20% of HR+ breast cancer patients showing primary resistance to endocrine therapy [12].